此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin

2026年9月8日 更新者:University of Colorado, Denver

The goal of this clinical trial is to learn how atorvastatin in patients with advanced high grade serous cancer of the ovary, fallopian tube, or peritoneum changes the tumor immune environment. The main question it aims to answer is:

  • Does atorvastatin combined with standard of care chemotherapy and surgery changes the number of tumor-promoting macrophages in the tumor microenvironment
  • Researchers will compare standard of care chemotherapy and surgery to see if there is a difference in tumor promoting macrophages.
  • Participants will take atorvastatin (daily pill) alongside their standard treatment.

研究概览

研究类型

介入性

注册 (估计的)

40

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Colorado
      • Aurora、Colorado、美国、80045
        • University of Colorado Anschutz

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Be a patient with ovarian cancer aged 18-89
  • Diagnosed via tissue biopsy not ascites
  • For persons of reproductive potential, use of highly effective method(s) of contraception.
  • Patients with primary Stage III/IV high-grade serous ovarian/fallopian tube/primary peritoneal cancer not amenable to upfront cytoreductive surgery.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
  • Absolute Neutrophil Count 1500 cells/mL
  • Platelet count > 100,000 mL.
  • Hemoglobin 9.0 g/dL
  • Serum albumin ³ 2.5 g/dL.
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN).
  • aspartate aminotransferase (AST )and alanine aminotransferase (ALT) ≤ 3.0 x ULN.
  • Serum creatinine ≤ 1.5x ULN

Exclusion Criteria:

  • Inability to comply with study and follow-up procedures.
  • Significant cardiovascular disease, such as New York Heart Association cardiac disease (class II or greater), myocardial infarction within the past 3 months, unstable arrhythmia, or unstable angina.
  • Known clinically significant liver disease defined as AST and ALT > 3.0 x ULN and/or total bilirubin ≥ 1.5 x ULN, or documented history of active viral, alcoholic, or other hepatitis, cirrhosis, and inherited liver disease.
  • Participation in investigational clinical trial within last 30 days.
  • Medical history of untreated HIV infection. Patients with medical history of HIV infection are eligible provided they meet following criteria

    • Are stable on antiretroviral therapy for ≥4 weeks before randomization
    • Agree to adhere to antiretroviral therapy per World Health Organization (WHO) guidelines
    • Have no documented multi-drug resistance that would prevent effective antiretroviral therapy
    • Have a viral load of <400 copies per mL at screening
    • Have CD4+ T cell count at ≥ 350 cells per μL
    • Have no history of acquired immunodeficiency syndrome (AIDS) -defining opportunistic infection ≤ 12 months before randomization.
  • Inability to provide informed consent.
  • Known central nervous system (CNS) malignancy or CNS metastases.
  • Patients with previous malignancy within the past 2 years from cycle 1, day 1, except those with negligible risk of metastasis or death, such as adequately controlled basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the breast.
  • History of stroke or transient ischemic attack (TIA) within 3 months prior to cycle 1 day 1(C1D1).
  • Patients with prognosis for survival less than 6 months.
  • Patients deemed otherwise clinically unfit for clinical trial per Investigator's discretion.
  • Patients with duodenal stent or other gastrointestinal (GI) disorder/defect that would interfere with absorption of oral medication.

    o Includes patients unable to swallow orally administered medication and patients with GI disorders likely to interfere with absorption of the study medication

  • Female patients who maintain fertility potential and refuse to comply to use contraception and be followed for pregnancy by pregnancy testing.
  • Patients who are currently pregnant or lactating.
  • Prior or current statin use that would prohibit randomization into SOC arm.
  • Planned treatment with bevacizumab in the primary treatment setting.
  • Diagnosis based on ascites assessment only and not a tissue biopsy.
  • Patients deemed otherwise clinically unfit for clinical trial per investigators discretion

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Standard of Care
neoadjuvant chemotherapy with 3-4 cycles of carboplatin/paclitaxel, interval debulking surgery, then 2-3 additional cycles of chemotherapy with carboplatin/paclitaxel
neoadjuvant chemotherapy with 3-4 cycles of carboplatin/paclitaxel, interval debulking surgery, then 2-3 additional cycles of chemotherapy with carboplatin/paclitaxel
实验性的:Atorvastatin with Standard of Care
Patients in this arm will take atorvastatin daily alongside neoadjuvant chemotherapy with 3-4 cycles of carboplatin/paclitaxel, interval debulking surgery, then 2-3 additional cycles of chemotherapy with carboplatin/paclitaxel
Neoadjuvant chemotherapy with carboplatin and paclitaxel in addition to daily atorvastatin, interval debulking surgery, then 2-3 additional cycles of carboplatin and paclitaxel

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from baseline of CD163+ tumor associated macrophages in post-treatment specimens.
大体时间:3 months
The primary efficacy endpoint is the change from baseline to the post-treatment surgical specimen in the mean CD163 H-score among CD68-positive tumor-associated macrophages. CD68 and CD163 expression will be assessed by multispectral immunohistochemistry in paired pre-treatment biopsy and post-treatment surgical samples.
3 months

次要结果测量

结果测量
措施说明
大体时间
Progression free survival
大体时间:5 years
Investigator-assessed progression-free survival will be defined as the time from randomization to the first documented occurrence of objective disease progression or death from any cause, whichever occurs first.
5 years
Overall Survival
大体时间:5 years
Overall survival as defined by the time of randomization to time of death from any cause.
5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Nicole Marjon, MD, PhD、CU Anschutz

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2028年8月1日

研究完成 (估计的)

2031年8月1日

研究注册日期

首次提交

2026年8月31日

首先提交符合 QC 标准的

2026年9月8日

首次发布 (实际的)

2026年9月11日

研究记录更新

最后更新发布 (实际的)

2026年9月11日

上次提交的符合 QC 标准的更新

2026年9月8日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

All data will be de-identified prior to sharing with other researchers

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅